<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853032</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160191H</org_study_id>
    <nct_id>NCT02853032</nct_id>
  </id_info>
  <brief_title>Image-guided, Robotically Delivered Transcranial Magnetic Stimulation Treatment for Combat-Related Post-Traumatic Stress Disorder</brief_title>
  <official_title>Image-guided, Robotically Delivered Transcranial Magnetic Stimulation Treatment for Combat-Related Post-Traumatic Stress Disorder: a Double-Blind, Randomized Comparison to Sham Transcranial Magnetic Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laurel Ridge Treatment Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Consortium to Alleviate PTSD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mounting amounts of evidence suggests that non-invasive stimulation of the dorsolateral&#xD;
      prefrontal cortex (DLPFC) using repetitive transcranial magnetic stimulation (rTMS) maybe a&#xD;
      safe and effective treatment modality for Post-Traumatic Stress Disorder (PTSD). However the&#xD;
      large variability in the magnitude of clinical outcomes reported is likely related to the&#xD;
      current lack of knowledge of ideal side of stimulation (left vs right) and the limited&#xD;
      precision in the targeting of brain circuits needed to obtain an optimal treatment response.&#xD;
      In this protocol the investigators will: 1) generate individualized treatment plans based on&#xD;
      an individual's functional Magnetic Resonance Imaging (fMRI) and meta-analytical based&#xD;
      connectivity analysis to guide the delivery of adjunct, imaging-based &amp; robotically delivered&#xD;
      rTMS to active duty military (ADM) subjects with PTSD participating in an intensive program&#xD;
      providing integrated evidence-based psychotherapy and pharmacological management (Treatment&#xD;
      as Usual (TAU)). 2) To use clinician ratings and self-report PTSD symptom scales, as well as&#xD;
      other indicators of clinical change, to determine whether compared with TAU, addition of&#xD;
      adjunct rTMS improves clinical outcomes. 3) To conduct neuroimaging-based assessments aimed&#xD;
      to measure rTMS effects on network connectivity in ADM receiving treatment for PTSD and the&#xD;
      potential correlation of connectivity changes with clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a randomized, double-blind, sham-controlled, 20 consecutive day&#xD;
      trial of adjunct rTMS to the right DLPFC for ADM with PTSD receiving TAU at Laurel Ridge&#xD;
      Treatment Center (LRTC; San Antonio, TX). Methods: Consenting ADM receiving TAU for PTSD at&#xD;
      LRTC will be randomized to receive 20 consecutive days of adjunct rTMS according to one of&#xD;
      these two treatment arms: Arm 1 TAU plus rTMS to the right DLPFC and Arm 2 TAU plus sham&#xD;
      rTMS. At UTHSCSA's Research Imaging Institute (RII), where all brain imaging will be&#xD;
      conducted, rTMS treatment plans will be generated based on (pre-treatment) anatomical and&#xD;
      functional magnetic resonance imaging (fMRI) to guide the optimal robotic positioning of the&#xD;
      TMS coil to accurately target each subject's DLPFC. Initial diagnostic interview and weekly&#xD;
      clinical follows ups will be conducted at the LRTC by research clinicians blinded to&#xD;
      subjects' research group. A comparison of baseline brain connectivity measurements with&#xD;
      subjects' neuroimaging follow ups conducted at treatment Week 3 will be conducted to identify&#xD;
      network connectivity changes potentially associated to treatment response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PTSD Severity as Measured by the PTSD Checklist (PCL-5)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD Severity as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD Severity as Measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD Severity as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD Severity as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
A clinically significant response is defined as at least a 50% decrease in the CAPS-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
A clinically significant response is defined as at least a 50% decrease in the CAPS-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From PTSD as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
Remission is defined as a CAPS-5 score less than or equal to 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From PTSD as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
Remission is defined as a CAPS-5 score less than or equal to 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Connectivity Changes (Measured by Resting-state Functional Magnetic Resonance Imaging) of the Targeted Brain Network(s) Following rTMS Treatment</measure>
    <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
    <description>Resting-state brain networks were identified using functional Magnetic Resonance Imaging. Any changes in the the targeted brain network (e.g. the sub-genual cingulate cortex) were reported using functional connectivity Z-scores. Functional connectivity Z-score indicates the number of standard deviations away from the baseline mean. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean, and lower connectivity, and positive numbers indicate values higher than the baseline mean, and higher connectivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events</measure>
    <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
    <description>This measure counts the number of participants with adverse events and serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Active rTMS to the right DLPFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS to the right DLPFC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active repetitive transcranial magnetic stimulation</intervention_name>
    <description>The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.</description>
    <arm_group_label>Active rTMS to the right DLPFC</arm_group_label>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>robotic arm</intervention_name>
    <description>This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.</description>
    <arm_group_label>Active rTMS to the right DLPFC</arm_group_label>
    <arm_group_label>Sham rTMS to the right DLPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham repetitive transcranial magnetic stimulation</intervention_name>
    <description>The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.</description>
    <arm_group_label>Sham rTMS to the right DLPFC</arm_group_label>
    <other_name>sham rTMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female English-speaking active duty or recently retired veteran patients who&#xD;
             have deployed post 9/11 receiving treatment at LRTC between the ages of 18-65 years;&#xD;
&#xD;
          2. Patients must have a diagnosis of PTSD confirmed by the Clinician-Administered PTSD&#xD;
             Scale (CAPS-5) at screening,&#xD;
&#xD;
          3. Subjects must have a minimum PTSD Symptom Checklist (PCL-5) for DSM-V symptom severity&#xD;
             rating of 25.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a diagnostic history of bipolar disorder, schizophrenia or&#xD;
             schizoaffective disorder as documented in the medical record.&#xD;
&#xD;
          2. Substance use disorder during the 12 months prior to screening; except that Mild -&#xD;
             Moderate, but not Severe, Alcohol Use Disorder (using DSM-5 criteria) will be allowed&#xD;
             as determined by LRTC medical provider review.&#xD;
&#xD;
          3. Any history or signs of serious medical or neurological illness including seizure&#xD;
             disorders. Except for seizures, a subject with a clinical abnormality may be included&#xD;
             only if the study clinician considers the illness will not introduce additional risk&#xD;
             and will not interfere with the study procedures. This will be determined during the&#xD;
             screening phase via self-report and/or medical history review.&#xD;
&#xD;
          4. History of traumatic brain injury (TBI) with loss of consciousness for 20 minutes or&#xD;
             more as determined by the History of Head Injuries questionnaire.&#xD;
&#xD;
          5. Females will be excluded if they are pregnant (i.e. positive pregnancy test identified&#xD;
             after their LRTC intake).&#xD;
&#xD;
          6. Any history or signs of metal objects deemed unsafe for MRI or that may adversely&#xD;
             affect image quality of the brain region (e.g. surgical clips, cardiac pacemakers,&#xD;
             metal implants, etc.) in the body at the time of screening as indicated by&#xD;
             self-report. MRI can have risks for persons with foreign bodies implanted in their&#xD;
             body.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe S Salinas, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laurel Ridge Treatment Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Boggio PS, Rocha M, Oliveira MO, Fecteau S, Cohen RB, Campanh√£ C, Ferreira-Santos E, Meleiro A, Corchs F, Zaghi S, Pascual-Leone A, Fregni F. Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. J Clin Psychiatry. 2010 Aug;71(8):992-9. doi: 10.4088/JCP.08m04638blu. Epub 2009 Dec 29.</citation>
    <PMID>20051219</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <results_first_submitted>March 26, 2020</results_first_submitted>
  <results_first_submitted_qc>October 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2020</results_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Felipe S. Salinas, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor--Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data at this time.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02853032/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active rTMS to Right DLPFC</title>
          <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
        </group>
        <group group_id="P2">
          <title>Sham rTMS to the Right DLPFC</title>
          <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51">&quot;Evaluable&quot; = 10 or more irTMS sessions &quot;Completers&quot; = 15 or more irTMS sessions</participants>
                <participants group_id="P2" count="56">&quot;Evaluable&quot; = 10 or more irTMS sessions &quot;Completers&quot; = 15 or more irTMS sessions</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requested to withdraw from all treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active rTMS to Right DLPFC</title>
          <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
        </group>
        <group group_id="B2">
          <title>Sham rTMS to the Right DLPFC</title>
          <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.48" spread="7.02"/>
                    <measurement group_id="B2" value="38.60" spread="6.35"/>
                    <measurement group_id="B3" value="38.10" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in PTSD Severity as Measured by the PTSD Checklist (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PTSD Severity as Measured by the PTSD Checklist (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.82" spread="10.07"/>
                    <measurement group_id="O2" value="60.45" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.29" spread="19.86"/>
                    <measurement group_id="O2" value="39.14" spread="19.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to the Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 28 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week; 20 consecutive days.&#xD;
Active repetitive transcranial magnetic stimulation: The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.&#xD;
robotic arm: This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system w</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 28 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.&#xD;
robotic arm: This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.&#xD;
Sham repetitive transcranial magnetic stimulation: The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.80" spread="5.24"/>
                    <measurement group_id="O2" value="19.31" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.67" spread="6.73"/>
                    <measurement group_id="O2" value="12.19" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to the Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 28 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week; 20 consecutive days.&#xD;
Active repetitive transcranial magnetic stimulation: The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.&#xD;
robotic arm: This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system w</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 28 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.&#xD;
robotic arm: This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.&#xD;
Sham repetitive transcranial magnetic stimulation: The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.55" spread="9.20"/>
                    <measurement group_id="O2" value="28.12" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.96" spread="10.22"/>
                    <measurement group_id="O2" value="16.17" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PTSD Severity as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PTSD Severity as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.82" spread="10.07"/>
                    <measurement group_id="O2" value="60.45" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>seven weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.35" spread="14.57"/>
                    <measurement group_id="O2" value="40.22" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PTSD Severity as Measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</title>
        <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PTSD Severity as Measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</title>
          <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="8.90"/>
                    <measurement group_id="O2" value="46.12" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>seven weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.83" spread="14.37"/>
                    <measurement group_id="O2" value="31.00" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.80" spread="5.24"/>
                    <measurement group_id="O2" value="19.31" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>seven weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="6.21"/>
                    <measurement group_id="O2" value="14.19" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.55" spread="9.20"/>
                    <measurement group_id="O2" value="28.12" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>seven weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.78" spread="11.74"/>
                    <measurement group_id="O2" value="19.75" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PTSD Severity as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PTSD Severity as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.82" spread="10.07"/>
                    <measurement group_id="O2" value="60.45" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sixteen weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.47" spread="19.06"/>
                    <measurement group_id="O2" value="46.64" spread="22.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PTSD Severity as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
        <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PTSD Severity as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
          <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="8.90"/>
                    <measurement group_id="O2" value="46.12" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sixteen weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.58" spread="14.27"/>
                    <measurement group_id="O2" value="31.45" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.80" spread="5.24"/>
                    <measurement group_id="O2" value="19.31" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sixteen weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.87" spread="7.31"/>
                    <measurement group_id="O2" value="16.86" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.55" spread="9.20"/>
                    <measurement group_id="O2" value="28.12" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.50" spread="14.31"/>
                    <measurement group_id="O2" value="21.75" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.03" spread="4.47"/>
                    <measurement group_id="O2" value="-36.53" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.04" spread="5.22"/>
                    <measurement group_id="O2" value="-31.61" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.75" spread="5.29"/>
                    <measurement group_id="O2" value="-40.74" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.44" spread="4.44"/>
                    <measurement group_id="O2" value="-34.28" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
        <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
A clinically significant response is defined as at least a 50% decrease in the CAPS-5.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
          <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
A clinically significant response is defined as at least a 50% decrease in the CAPS-5.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.84" spread="5.52"/>
                    <measurement group_id="O2" value="-29.59" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.47" spread="7.06"/>
                    <measurement group_id="O2" value="-13.28" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.40" spread="11.05"/>
                    <measurement group_id="O2" value="-24.42" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. A clinically significant response is defined as a 10-20 point decrease in the PCL-5 scores.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.20" spread="9.18"/>
                    <measurement group_id="O2" value="-17.01" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
        <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
A clinically significant response is defined as at least a 50% decrease in the CAPS-5.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
          <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
A clinically significant response is defined as at least a 50% decrease in the CAPS-5.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.32" spread="13.00"/>
                    <measurement group_id="O2" value="-27.64" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.35" spread="11.18"/>
                    <measurement group_id="O2" value="19.36" spread="23.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Response in Depression Severity as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Clinically significant response is defined as greater than or equal to a 50% decrease in the MADRS score.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.65" spread="12.86"/>
                    <measurement group_id="O2" value="-20.47" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.82"/>
                    <measurement group_id="O2" value="46.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.75"/>
                    <measurement group_id="O2" value="67.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.10"/>
                    <measurement group_id="O2" value="39.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.54"/>
                    <measurement group_id="O2" value="48.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From PTSD as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
        <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
Remission is defined as a CAPS-5 score less than or equal to 29.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From PTSD as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
          <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
Remission is defined as a CAPS-5 score less than or equal to 29.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.17"/>
                    <measurement group_id="O2" value="45.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.92"/>
                    <measurement group_id="O2" value="59.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
        <time_frame>Baseline to seven weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.43"/>
                    <measurement group_id="O2" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
        <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From PTSD as Measured by the PTSD Checklist for DSM-5 (PCL-5)</title>
          <description>The PCL-5 is a 20-item measure that assesses the presence and severity of PTSD symptoms. Responders are asked to rate how bothered they have been by each item in the past month on a 5-point Likert scale ranging from 0-4. Items are summed to provide a total score. Severity can be determined adding scores of each item together to determine a total score. The range is 0-80, with a lower score suggesting a lower incidence of PTSD. A total score of 33 or higher suggests the patient needs further assessment to confirm a diagnosis of PTSD. Remission is defined as a PCL-5 score less than or equal to 33.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From PTSD as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
        <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
Remission is defined as a CAPS-5 score less than or equal to 29.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From PTSD as Measured by the Clinician-Administered PTSD Scale (CAPS-5)</title>
          <description>The CAPS-5 is a 30-item structured interview that can be used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week. The assessor combines information about frequency and intensity of an item into a single severity rating. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms; the range of the scores is 0-80; with a higher score indicating a higher incidence of PTSD symptoms. To meet criteria for PTSD, a patient must have:&#xD;
A traumatic event&#xD;
At least one &quot;Re-experiencing&quot; symptom&#xD;
At least one &quot;Avoidance&quot; symptom&#xD;
At least two &quot;Negative alterations in cognitions and mood&quot; symptoms&#xD;
At least two &quot;Alterations in arousal and reactivity&quot; symptoms&#xD;
The trauma must last at least a month&#xD;
The trauma must cause impairment&#xD;
Remission is defined as a CAPS-5 score less than or equal to 29.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.67"/>
                    <measurement group_id="O2" value="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
        <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From Depression as Measured by the 9-item Patient Health Questionnaire (PHQ-9)</title>
          <description>The PHQ-9 is a brief, 9-item scale that includes only the depression-related items from the PHQ. The PHQ-9 has been validated for use in primary care settings and can be used to make a tentative diagnosis of depression and to monitor depression severity and response to treatment in the past 2 weeks. Higher scores indicate increasing depressive symptoms. Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Remission from severe depression is defined as a PHQ-9 score less than or equal to 14.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="35.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission From Depression as Measured by the Montgomery-Ashberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60. Higher scores indicate increasing depressive symptoms. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. Remission from depression is defined as a MADRS score less than or equal to 10.</description>
          <population>Discrepancies in the number of participants analyzed for this outcome measure occur because of 1) incomplete assessments at the designated outcome measure's time frame or 2) because the participant did not complete more than 15 treatment sessions, but were considered &quot;evaluable&quot; (&gt;10 sessions).</population>
          <units>percentage of patients remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Connectivity Changes (Measured by Resting-state Functional Magnetic Resonance Imaging) of the Targeted Brain Network(s) Following rTMS Treatment</title>
        <description>Resting-state brain networks were identified using functional Magnetic Resonance Imaging. Any changes in the the targeted brain network (e.g. the sub-genual cingulate cortex) were reported using functional connectivity Z-scores. Functional connectivity Z-score indicates the number of standard deviations away from the baseline mean. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean, and lower connectivity, and positive numbers indicate values higher than the baseline mean, and higher connectivity</description>
        <time_frame>Baseline to three weeks (the conclusion of rTMS treatment)</time_frame>
        <population>Functional brain connectivity to the sub-genual cingulate (SGC) cortex compared between the Active and Sham groups (in participants with &gt;15 treatment sessions) at baseline and 3 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Connectivity Changes (Measured by Resting-state Functional Magnetic Resonance Imaging) of the Targeted Brain Network(s) Following rTMS Treatment</title>
          <description>Resting-state brain networks were identified using functional Magnetic Resonance Imaging. Any changes in the the targeted brain network (e.g. the sub-genual cingulate cortex) were reported using functional connectivity Z-scores. Functional connectivity Z-score indicates the number of standard deviations away from the baseline mean. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean, and lower connectivity, and positive numbers indicate values higher than the baseline mean, and higher connectivity</description>
          <population>Functional brain connectivity to the sub-genual cingulate (SGC) cortex compared between the Active and Sham groups (in participants with &gt;15 treatment sessions) at baseline and 3 weeks.</population>
          <units>z-score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02"/>
                    <measurement group_id="O2" value="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events</title>
        <description>This measure counts the number of participants with adverse events and serious adverse events.</description>
        <time_frame>Baseline to sixteen weeks (twelve weeks after the conclusion of rTMS treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active rTMS to Right DLPFC</title>
            <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS to the Right DLPFC</title>
            <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events</title>
          <description>This measure counts the number of participants with adverse events and serious adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>SAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>UPIRSO</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>none</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Sixteen weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active rTMS to Right DLPFC</title>
          <description>Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
        </group>
        <group group_id="E2">
          <title>Sham rTMS to the Right DLPFC</title>
          <description>Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Claustrophobia during MRI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Increased Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Numbness in Extremities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscle Twitching</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Facial Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Unable to tolerate TMS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Felipe S. Salinas, Ph.D.</name_or_title>
      <organization>University of Texas Health -- San Antonio</organization>
      <phone>210-567-8214</phone>
      <email>salinasf@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

